Blood will out

For every spectacular success, such as Gilead’s Pharmasset deal, there were several embarrassing flops, like Teva’s purchase of Allergan’s generic assets.

The year in review

In 2019, we saw an avalanche of legal manoeuvrings and proposed settlements with companies like Purdue, Johnson and Johnson, McKesson, AmeriSource Bergen, Cardinal Health and Teva now offering to pay jurisdictions

Allergan gets FDA nod for first oral CGRP drug for migraine

First to market among these the injectables was Amgen/Novartis’ Aimovig (erenumab), and it has since been joined by Eli Lilly’s Emgality (galcanezumab) and Teva’s Ajovy (fremanezumab), with intravenous

J&J appeals Oklahoma opioid verdict, claiming ‘errors’ in trial

Oklahoma also sued Teva Pharmaceuticals and Purdue Pharma, with both of these companies ultimately deciding to settle out of court (for $85m and $270m respectively).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]